Biomerica, Inc. (BMRA) financial statements (2022 and earlier)

Company profile

Business Address 17571 VON KARMAN AVENUE
IRVINE, CA 92614
State of Incorp. DE
Fiscal Year End May 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

11/30/2021
TTM
5/31/2021
5/31/2020
5/31/2019
5/31/2018
5/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,1994,1998,6416871,2051,225
Cash and cash equivalents7,1994,1998,6416871,2051,225
Receivables1,0971,4551,7661,4558001,060
Inventory, net of allowances, customer advances and progress billings2,9823,2062,8512,1512,1791,729
Inventory2,9823,2062,8512,1512,1791,729
Other undisclosed current assets1,1253701,509202300196
Total current assets:12,4039,23114,7674,4954,4844,210
Noncurrent Assets
Operating lease, right-of-use asset1,4271,5531,712
Property, plant and equipment274311279351351332
Intangible assets, net (including goodwill)38929516910799174
Intangible assets, net (excluding goodwill)38929516910799174
Other noncurrent assets15026416812711395
Deferred tax assets, net 1041
Other undisclosed noncurrent assets165165165165165165
Total noncurrent assets:2,4062,5882,493750739808
TOTAL ASSETS:14,80911,81917,2605,2455,2235,018
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,5815839871,038687352
Accounts payable 432    
Accrued liabilities 152    
Employee-related liabilities674 279227210177
Other undisclosed accounts payable and accrued liabilities906 708811477175
Other undisclosed current liabilities3,160717490227210177
Total current liabilities:4,7411,3001,4771,264897529
Noncurrent Liabilities
Long-term debt and lease obligation1,1671,2921,570   
Operating lease, liability1,1671,2921,570
Other undisclosed noncurrent liabilities(1,167)(1,292)(1,570)   
Total noncurrent liabilities:1,1671,2921,570   
Total liabilities:5,9082,5923,0471,264897529
Stockholders' equity
Stockholders' equity attributable to parent8,9019,22714,2133,9814,3264,489
Preferred stock  26   
Common stock1,015985939774711681
Additional paid in capital41,15938,83735,21422,83020,84419,552
Accumulated other comprehensive loss(58)(48)(40)(37)(26)(16)
Accumulated deficit(33,214)(30,546)(21,926)(19,587)(17,194)(15,728)
Stockholders' equity note, subscriptions receivable    (9) 
Total stockholders' equity:8,9019,22714,2133,9814,3264,489
TOTAL LIABILITIES AND EQUITY:14,80911,81917,2605,2455,2235,018

Income statement (P&L) ($ in thousands)

11/30/2021
TTM
5/31/2021
5/31/2020
5/31/2019
5/31/2018
5/31/2017
Revenues8,0177,1996,6935,2015,5645,792
Revenue, net 5,792
Cost of revenue(7,482)(6,833)(4,911)(3,909)(3,810)(3,770)
Gross profit:5343661,7821,2921,7542,022
Operating expenses(7,194)(7,866)(4,185)(3,705)(3,236)(2,976)
Operating loss:(6,660)(7,500)(2,403)(2,413)(1,482)(955)
Nonoperating income396671444846
Investment income, nonoperating396771444846
Interest and debt expense(0)(0)(0)(0)(0)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(1) 0000
Loss from continuing operations before equity method investments, income taxes:(6,621)(7,434)(2,332)(2,369)(1,434)(909)
Other undisclosed income from continuing operations before income taxes10    
Loss from continuing operations before income taxes:(6,621)(7,433)(2,332)(2,369)(1,434)(909)
Income tax expense(15)(13)(7)(24)(32) 
Net loss available to common stockholders, diluted:(6,635)(7,446)(2,339)(2,393)(1,466)(909)

Comprehensive Income ($ in thousands)

11/30/2021
TTM
5/31/2021
5/31/2020
5/31/2019
5/31/2018
5/31/2017
Net loss:(6,635)(7,446)(2,339)(2,393)(1,466)(909)
Other comprehensive income     2
Comprehensive loss:(6,635)(7,446)(2,339)(2,393)(1,466)(906)
Other undisclosed comprehensive loss, net of tax, attributable to parent(9)(8)(3)(10)(10)(4)
Comprehensive loss, net of tax, attributable to parent:(6,645)(7,454)(2,342)(2,403)(1,476)(911)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: